shrinking 12% to €318 million amid pressure from newer drugs. Mavenclad (cladribine) added €89 million in the quarter – more than three times the €25 million reported a year ago – thanks ...
NICE’s latest decision on the drug was supported by clinical and real-world evidence demonstrating that Mavenclad can reduce MS relapse rates and slow disability progression. The agency is now ...
US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback